HC Wainwright Brokers Reduce Earnings Estimates for SRTS

Sensus Healthcare, Inc. (NASDAQ:SRTS) – HC Wainwright reduced their Q2 2025 earnings estimates for shares of Sensus Healthcare in a research report issued to clients and investors on Monday, February 10th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.07 per share for the quarter, down from their prior estimate of $0.10. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s FY2025 earnings at $0.44 EPS.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Other analysts have also issued research reports about the stock. Maxim Group lifted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Lake Street Capital initiated coverage on Sensus Healthcare in a research note on Friday, January 31st. They set a “buy” rating and a $18.00 price target on the stock.

Sensus Healthcare Price Performance

NASDAQ SRTS opened at $5.93 on Wednesday. Sensus Healthcare has a one year low of $2.91 and a one year high of $9.33. The business has a 50 day simple moving average of $7.33 and a 200 day simple moving average of $6.89. The stock has a market capitalization of $97.19 million, a P/E ratio of 14.83 and a beta of 1.24.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SRTS. Truvestments Capital LLC bought a new position in Sensus Healthcare during the 3rd quarter valued at $32,000. IFP Advisors Inc bought a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $95,000. Cubist Systematic Strategies LLC purchased a new position in shares of Sensus Healthcare in the 2nd quarter worth approximately $156,000. XTX Topco Ltd grew its stake in Sensus Healthcare by 76.0% in the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Sensus Healthcare during the fourth quarter worth about $189,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.